Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionAnti-CD40L-Tn3 fusion protein
Molecular Target CD40 ligand (CD40L) (CD40LG) (CD154)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard IndicationSjogren's syndrome
Indication DetailsTreat primary Sjogren's syndrome
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today